Vir Biotechnology Inc
VIR
ISIN US92764N1028 / Valor 47821156
Vir Biotechnology Inc
UMushroom community rating:
About company
Vir Biotechnology Inc is a biotechnology company with a focus on leveraging its expertise in immunology and virology to develop innovative solutions for infectious diseases. The company's core capabilities include a monoclonal antibody platform with AI-led protein engineering capabilities, as well as a T cell-based viral vector platform. Vir aims to drive patient impact and growth in the field of infectious disease through the development of novel therapies.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.08.2024):
Revenue Growth
Vir Biotechnology Inc. reported total revenues of $59.45 million for the second quarter of 2024, a significant increase from the $3.08 million reported in the same quarter of 2023. This growth was primarily driven by higher collaboration and contract revenues.
Operating Expenses
For the second quarter of 2024, Vir Biotechnology Inc.'s total operating expenses were $218.98 million, compared to $168.08 million in the second quarter of 2023. The increase in operating expenses was mainly due to higher research and development costs and selling, general, and administrative expenses.
Net Loss
Vir Biotechnology Inc. reported a net loss of $203.65 million for the second quarter of 2024, compared to a net loss of $194.77 million in the same period of 2023. The increased net loss was attributed to higher operating expenses despite the rise in revenues.
Stockholders' Equity
As of June 30, 2024, Vir Biotechnology Inc.'s total stockholders' equity stood at $1.43 billion, down from $1.59 billion as of December 31, 2023. The decrease in stockholders' equity was primarily due to the net loss incurred during the first half of 2024.
Cash Flow
Vir Biotechnology Inc. reported net cash used in operating activities of $49.68 million for the first half of 2024, compared to $181.11 million used in the same period of 2023. The company also reported net cash provided by investing activities of $240.03 million, primarily from the maturities and sales of investments.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
1278 M
Market cap (USD)
206,906
Daily traded volume (Shares)
8.14 / 7.9
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
